Does Semaglutide Cause Cancer? The Thyroid Risk, the Evidence, and What Isn’t Proven Yet

Medically reviewed health explainer  ·  Last updated: May 2026

If you have read about semaglutide and seen the word cancer in the same sentence, you are not alone in feeling worried. 

This guide walks through what is actually proven, what is a warning based on animal data, and what the most recent human studies say.

1. So, does semaglutide actually cause cancer?

Based on current human evidence, semaglutide has not been shown to cause cancer in people. The strongest concern, thyroid C-cell tumours, comes from studies in mice and rats, not human trials.

A 2025 pooled analysis published in Diabetes, Obesity and Metabolism looked at 101,732 participants across 93 phase 2 and 3 trials of liraglutide or semaglutide, with 207,045 patient-years of exposure. 

Thyroid cancer occurred in 0.08% of GLP-1 users, 0.06% of placebo users, and 0.03% on active comparators. The difference was not statistically significant once the data was matched (Vilsbøll et al., 2025).

A separate 2024 systematic review in the International Journal of Molecular Sciences reviewed 10 randomised trials with 14,550 participants (7,830 on semaglutide). 

Thyroid cancer incidence was less than 1% and the authors concluded there was no signal of carcinogenesis (Feier et al., 2024).

That said, the FDA boxed warning has not been removed. Animal data is real, the underlying biology is plausible, and long-term follow-up beyond a decade is still being built. 

The honest answer right now: no proven human cancer risk, but the warning stays as a precaution.

2. What is the FDA black box warning really saying?

The FDA boxed warning on Ozempic, Wegovy, and Rybelsus is the most serious type of warning the regulator issues. It is built on two findings.

First, in lifetime studies in mice and rats, semaglutide caused dose-dependent and duration-dependent thyroid C-cell tumours, including medullary thyroid carcinoma, at clinically relevant plasma exposures.

Second, human relevance is unknown. The label explicitly states: “It is unknown whether semaglutide causes thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), in humans.”

Importantly, no C-cell tumours were observed in monkeys after 52 weeks of exposure at up to 27 times the clinical dose.

 Rodents have far more GLP-1 receptors on thyroid C-cells than primates, which is part of why the rodent signal may not translate (Novo Nordisk clinical study report).

3. Why was thyroid cancer flagged in the first place?

Thyroid C-cells produce calcitonin, a hormone involved in calcium regulation. GLP-1 receptors sit on these cells, and in rodents, those receptors are highly active. 

When semaglutide binds to them over a lifetime of exposure, the C-cells can multiply abnormally and form tumours.

Two facts make rodent extrapolation harder. First, humans have far fewer GLP-1 receptors on thyroid C-cells than mice and rats. 

Second, the doses needed to produce C-cell tumours in rodents are sustained at very high exposures across the animal’s full lifespan, which is hard to replicate in clinical use.

A French nationwide case-control study did find a 46% higher risk of all thyroid cancers and a 78% higher risk of medullary thyroid cancer in people on GLP-1 receptor agonists for 1 to 3 years. 

But these findings have not been confirmed in randomised trials, and detection bias is a real concern: people on these drugs see doctors more often, get more thyroid checks, and are more likely to have small tumours found incidentally (Bezin et al., 2023).

More rigorous randomised trial meta-analyses have found no statistically significant link between GLP-1 use and thyroid cancer when controlling for these biases (Duchemin et al., 2025).

4. What about pancreatic, breast, and other cancers?

This is where the picture gets more nuanced. There are signals in different directions, and they need to be read carefully.

Pancreatic cancer

Concerns about pancreatic cancer started in 2011 with FDA Adverse Event Reporting System (FAERS) data on exenatide, an earlier GLP-1 drug. 

A 2023 FAERS analysis found a 9.86-fold higher reporting rate for pancreatic cancer with GLP-1 drugs compared to other diabetes medicines (FAERS pharmacovigilance review).

But FAERS data has known reporting bias and cannot establish cause. When researchers analysed randomised trials and cohort studies instead, the signal disappeared. A 2024 cohort of 543,595 patients followed for over 7 years found no increased pancreatic cancer risk (OR 0.50, 95% CI 0.15–1.71). 

A 2025 meta-analysis of 62 trials with 66,232 participants also found no significant association (Wen et al., 2025).

Breast and postmenopausal cancer

The Wang et al. 2024 JAMA Network Open study of 1.6 million people with type 2 diabetes did not find a significant reduction in postmenopausal breast cancer (HR 1.07, 95% CI 0.93–1.23) compared to insulin users. 

It also did not find a significant effect on thyroid cancer either way (HR 0.99) (Wang et al., 2024).

Kidney cancer

A 2025 JAMA Oncology study of 86,632 adults with obesity by Dai and colleagues found a small, non-significant trend toward higher kidney cancer risk in GLP-1 users. 

This is a marginal signal that needs more follow-up (Dai et al., 2025).

Snapshot of human evidence by cancer type:

5. Could semaglutide actually protect against some cancers?

This is the part of the conversation that is gaining momentum, but it deserves heavy hedging. Several large observational studies suggest GLP-1 drugs may lower the risk of certain obesity-associated cancers. 

The findings are striking, but they are associations, not proven cause-and-effect.

The Wang et al. 2024 study of 1.6 million people with type 2 diabetes found that GLP-1 receptor agonists were linked to a lower risk of 10 of 13 obesity-associated cancers compared to insulin use, including reduced risk of colorectal, gallbladder, kidney, oesophageal, liver, ovarian, endometrial, multiple myeloma, meningioma, and pancreatic cancer (Wang et al., 2024).

The Dai et al. 2025 JAMA Oncology study of 86,632 adults with obesity found an overall 17% lower cancer risk in GLP-1 users compared to matched non-users, with the strongest signals for endometrial cancer, ovarian cancer, and meningioma (Dai et al., 2025).

Two limitations matter. First, these are observational studies, and people prescribed GLP-1 drugs differ in many ways from people who are not (income, healthcare access, lifestyle). 

Second, sustained weight loss itself is known to lower obesity-linked cancer risk, so part of the benefit may simply be the weight reduction, not the molecule. 

A 2025 Cancers review specifically flagged these methodological pitfalls (Harris, Harvie & Renehan, 2025).

Until randomised trials specifically designed to measure cancer outcomes are completed, “semaglutide may reduce cancer risk in people with obesity” is the most precise way to describe what we know. It is encouraging, not proven.

6. What does this mean for the Indian context?

India approved Wegovy in 2025, and the semaglutide patent expired in March 2026, opening the market to generic manufacturers. 

This means access is widening rapidly, and the conversation about long-term safety is becoming more relevant for Indian patients (Novo Nordisk India regulatory data).

Three issues are particularly relevant for the Indian population.

Thyroid disease prevalence. India has high rates of thyroid disorders, particularly hypothyroidism. 

A 2013 epidemiological study estimated that around 10.95% of Indian adults have hypothyroidism (Unnikrishnan et al., 2013, Indian Journal of Endocrinology and Metabolism). This makes a thorough thyroid history before starting semaglutide even more important.

Lower BMI threshold for metabolic risk. South Asians develop diabetes, hypertension, and cardiovascular disease at lower BMIs than Western populations. The ICMR-INDIAB study found type 2 diabetes prevalence of 11.4% in adults across India, with rates of pre-diabetes at 15.3% (Anjana et al., 2023, The Lancet Diabetes & Endocrinology). 

The Indian Council of Medical Research uses BMI cut-offs of 23 kg/m² for overweight and 25 kg/m² for obesity, which are lower than the global standard.

Generic semaglutide and quality assurance. With generics entering the Indian market, sourcing matters. Counterfeit and compounded semaglutide products have already been flagged as a safety concern globally. Only buy from a licensed pharmacy and verify the batch with the prescribing doctor.

7. What should you do if you are already on semaglutide?

If you are currently on semaglutide for diabetes or weight management, do not stop the medication abruptly based on cancer concerns alone. 

Stopping suddenly can lead to rapid weight regain, blood sugar swings, and reduced cardiovascular protection.

Talk to your prescribing doctor about your individual risk factors. Three reasonable steps are worth raising.

1. Review your thyroid history. If you or a first-degree relative has had medullary thyroid cancer or MEN 2, semaglutide should be stopped and an alternative treatment chosen.
2. Stay alert to warning symptoms. A lump or swelling in the neck, persistent hoarseness, trouble swallowing, or new shortness of breath should be evaluated promptly. These are the same symptoms the FDA label specifies in patient counselling.
3. Maintain regular check-ups. Annual or biannual reviews with your endocrinologist help catch any thyroid changes early and monitor for other side effects, including pancreatitis and gallbladder symptoms.

Semaglutide has well-documented benefits beyond weight loss: a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and existing cardiovascular disease, per the SELECT trial published in New England Journal of Medicine (Lincoff et al., 2023). 

For most users without contraindications, the benefit-risk balance currently favours continued use under medical supervision.

Frequently Asked Questions

Does semaglutide cause cancer?

Based on current human data, semaglutide has not been shown to cause cancer. The FDA boxed warning is based on rodent studies showing thyroid C-cell tumours, but human relevance is unknown. 

The largest pooled analyses of over 100,000 trial participants have found no statistically significant increase in thyroid or other cancers. Talk to your doctor about your personal risk before starting.

What is the thyroid cancer risk with semaglutide and is it proven?

The thyroid cancer risk is not proven in humans. It is based on dose-dependent C-cell tumours observed in mice and rats. 

Some French observational data suggested a 46% increase in thyroid cancer risk with GLP-1 use, but this has not been confirmed in randomised trials and may reflect detection bias. 

People with a personal or family history of medullary thyroid carcinoma or MEN 2 should avoid semaglutide entirely.

Is there any evidence semaglutide protects against certain cancers?

Emerging observational evidence suggests possible protection against several obesity-associated cancers, including colorectal, liver, endometrial, ovarian, gallbladder, and meningioma. 

The Wang et al. 2024 study of 1.6 million patients and the Dai et al. 2025 study of 86,632 adults both found lower cancer rates in GLP-1 users. 

However, this is associational, not proven cause-and-effect. Speak to your doctor for an individualised assessment.

Can people who have had cancer take semaglutide for weight loss?

This depends on the cancer type, time since treatment, and current health status. Most clinical trials have excluded people with active malignancy or recent cancer history within the past 5 years. 

For weight management after cancer treatment, the decision should be made jointly with your oncologist and treating physician based on your individual case.

Should I get a thyroid scan before starting semaglutide?

Routine thyroid imaging is not currently required by the FDA or Indian regulatory guidelines before starting semaglutide. 

What is required is a thorough history-taking to rule out personal or family history of medullary thyroid carcinoma or MEN 2. 

Thyroid function tests may be ordered if clinically indicated. Always work with a qualified prescribing doctor.

Related reading on semaglutide cancer risk

• What is semaglutide? Understanding the drug behind the warning